SPRO · Spero Therapeutics, Inc.

Spero Therapeutics Inc Is A Clinical-Stage Biopharmaceutical Firm. It Focuses On Identifying, Developing, And Commercializing Novel Treatments For Mdr (Multi-Drug-Resistant) Bacterial Infections And Rare Diseases. The Company'S Product Candidate, Tebipenem Pivoxil Hydrobromide Or Tebipenem Hbr, Is Designed To Be An Oral Carbapenem-Class Antibiotic For Use In Adults To Treat Mdr Gram-Negative Infections. It Is Also Developing Spr720, A Novel Oral Antibiotic Designed For The Treatment Of A Rare, Orphan Disease Caused By Pulmonary Non-Tuberculous Mycobacterial Infections, Or Ntm Disease. It Is Also Focused On Spr206, A Next-Generation Polymyxin Investigational Product Candidate Being Developed As An Iv-Administered Medicine To Treat Mdr Gram-Negative Infections In The Hospital.